BGLC (BioNexus Gene Lab) Growth Rank: 1 (As of Sep. 07, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLC BioNexus Gene Lab Corp BGLC
56 GF Score
Price $1.45
GF Value $1.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is BioNexus Gene Lab Growth Rank?

BioNexus Gene Lab BGLC -1.36% 56 Growth Rank is 1 as of Sep. 07, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates BGLC with a GF Score™ of 56/100 and a GF Value™ of $1.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

BioNexus Gene Lab has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

BioNexus Gene Lab Growth Rank Related Terms

BGLC vs CNEY, SNES, QGAI: Growth Rank Comparison

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNexus Gene Lab Growth Rank vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Growth Rank distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Growth Rank falls into.


BGLC
56GF Score
BioNexus Gene Lab Corp BGLC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
BioNexus Gene Lab (BGLC) has a Growth Rank of 1 as of Sep. 07, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on BioNexus Gene Lab and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, BioNexus Gene Lab's Growth Rank has ranged from 1.00 to 4.00.
Is BioNexus Gene Lab's Growth Rank too high?
BioNexus Gene Lab's current Growth Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Growth Rank compare to CNEY and SNES?
BioNexus Gene Lab's Growth Rank of 1 can be compared against companies in the Chemicals industry. Historically, BioNexus Gene Lab's own Growth Rank has ranged from 1.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Chemicals company?
A good Growth Rank depends on the Chemicals industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Growth Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $1.45 — trading 16.9% above its estimated fair value. The current Growth Rank is 1, which is 50% below median its 10-year median of 2.00. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Growth Rank is 1 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNexus Gene Lab (BGLC) Overvalued in 2026?

Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued. The current stock price of $1.45 is trading 16.9% above its estimated GF Value™ of $1.24. GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.

Key valuation signals for BGLC:

  • Growth Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: $1.24 vs. price of $1.45 (16.9% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNexus Gene Lab Business Description

Address No.5 Jln Bangsar Utama 1, Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score

Get the complete analysis for BGLC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.45
Price
$1.24
GF Value